GSK plc with ticker (LON:GSK) now has a potential upside of .9% according to Barclays.
Barclays set a target price of 1,575 GBX for the company, which when compared to the GSK plc share price of 1,560 GBX at opening today (12/01/2024) indicates a potential upside of .9%. Trading has ranged between 1,303 (52 week low) and 1,726 (52 week high) with an average of 6,175,604 shares exchanging hands daily. The market capitalisation at the time of writing is £64,425,644,507.
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).
GSK plc .9% potential upside indicated by Barclays
- Written by: Charlotte Edwards
Latest Company News
TESARO, part of GSK, has filed a case in the Delaware Chancery Court claiming AnaptysBio has breached its licence agreement for the cancer treatment Jemperli.
GSK reported Q3 2025 sales of £8.5 billion, up 8% at constant exchange rates, driven by strong performances across Specialty Medicines, Vaccines and General Medicines.
GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK5764227 (GSK'227), has been granted Orphan Drug Designation by the European Medicines Agency for treating pulmonary neuroendocrine carcinoma, including small-cell lung cancer.
GSK has received FDA approval for Blenrep (belantamab mafodotin-blmf) with bortezomib and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least two prior therapies.
GSK has announced the appointment of Luke Miels as CEO Designate, with full responsibilities and a Board position from 1 January 2026. Currently Chief Commercial Officer, Luke has been key in expanding GSK’s specialty medicines and vaccines portfolio, bringing senior experience from AstraZeneca, Roche and Sanofi-Aventis.
GSK has announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 and over.
